A Study of 1592U89 in HIV-Infected Adults

Inclusion Criteria Concurrent Medication: Allowed: Erythropoietin, G-CSF and GM-CSF. Patients must have: * CD4+ cell count \< 100 cells/mm3. * HIV-1 RNA \> 30,000 copies/ml. * Signed, informed consent from parent or legal guardian for patient under 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Renal failure requiring dialysis. * Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper limit of normal. * Documented hypersensitivity to 1592U89. * Serious medical conditions, such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the patient. * Participation in or ability to participate in an enrolling study of 1592U89. Required: At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different regimens with at least one protease inhibitor). Alcohol or illicit drug use that may interfere with the patient's compliance.